pazo2

PAZ02: For Investigators


PaZ02: A study of pazopanib efficacy and safety in patients with advanced clear cell renal cell carcinoma and ECOG Performance Status 2: A phase II single arm multicentre study


Change of Staff

If there is a change of staff working on the trial please print off and complete the relevant registration form below. Please also ensure that the Signature and Delegation Log is updated. Return both documents to the PAZ02 Trial Office.

  • Site Staff Registration Form [.pdf]
  • Site Staff Signature and Delegation Log [.pdf]

Trial Documents

Links to the current protocol, Patient Information Sheet, Informed Consent Form are provided below. If there has been a recent amendment to the trial please ensure you have R&D approval before using these documents.

Other documents (e.g. Amendments, Case Report Form, Serious Adverse Event Form, Guidelines, GP Letter, Release of Medical Information Form etc) can be found by clicking on the other menu items below. If you cannot find what you are looking for please contact the PAZ02 Trial Office.

  • Trial protocol [.pdf]
  • Patient Information Sheet [.pdf]
  • Informed Consent Form [.pdf]

Version Control Lists

The version numbers and dates of all documents used for the trial are captured on a Version Control List. Links to the Version Control Lists used in this trial are below in reverse date order.

  • Document Version Control V7.0 [.pdf]

Amendments

Below is a link to a document which lists all of the substantial protocol amendments which have been made for this trial. The folders below contain the relevant amended documentation and approval letters. Please ensure that you have R&D approval (if applicable) before using the latest versions of these documents.

  • Amendment 1
  • Amendment 2
  • Amendment 3
  • Amendment 4
  • Amendment 5
  • Amendment 6
  • Amendment 7
  • Amendment 8
  • Amendment 9
  • Amendment 10
  • Amendment 11
  • Amendment 12
  • Amendment 13
  • Amendment 14
  • Amendment 15
  • Amendment 16
  • Amendment 17

Case Report Form

  • CRF version control checklist v9.0 [.pdf]
  • Eligibility Checklist v2.1 [.pdf]
  • Registration form v2.1 [.pdf]
  • Baseline form v5.1 [.pdf]
  • Treatment Forms
    • Week 2 v7.1 [.pdf]
    • Week 4 v7.1 [.pdf]
    • Week 6 v7.1 [.pdf]
    • Week 8 v7.1 [.pdf]
    • 4 Weekly v7.1 (Week 12 onwards treatment form) [.pdf]
  • End of Treatment Form v7.1 [.pdf]
  • 3 Monthly Follow Up Form v7.1 [.pdf]
  • Death Form v1.1 [.pdf]
  • Deviation Form v2.1 [.pdf]
  • Withdrawal Form v3.1 [.pdf]
  • Pregnancy Notification Form v1.1 [.pdf]
  • Disease Progression Form v5.1 [.pdf]
  • SAE Form v1.1 [.pdf]
  • SAE Fax Cover Sheet v3.1 [.pdf]

Guidelines

  • CRF Completion Guidelines v1.0 [.pdf]
  • SAE Form Completion Guidelines v1.0 [.pdf]

Other Trial Documents

  • Pharmacy Manual v2.0 [.pdf]
  • SmPC Pazopanib dated 06-Aug-2015 [.pdf]

Publications

To date there are no publications for this trial. 

News and Events

A protocol amendment is planned for submission soon. All sites will receive the amendment documents once approval has been obtained. 

Changes to CRCTU trials staff
A new Senior Trial Coordinator has joined Team A - Donna Smith.

1 more patient is needed to reach the 75 patient target
Newsletter June 2016

Contact Details

Chief Investigator
Dr Emilio Porfiri
Cancer Research UK Clinical Trials Unit (CRCTU)
University of Birmingham
Birmingham
B15 2TT

PAZO2 Trial Office
Trial Coordinator:                                 Anne-Marie Hodgkins
Data Manager:                                      Gavin Nixon
Trial Monitor:                                        Shaneed Hajee

Trial Management Team Leader:       Sarah Bowden
Trial Statistician:                                    Sarah Pirrie

Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT

Enquiries
Telephone: +44 (0) 121 414 7671
Fax: +44 (0) 414 2230
Email: Pazo2@trials.bham.ac.uk

Trial Entry
Telephone: 0800 371 969 or 0121 414 3797    (9.00 am till 5.00 pm Monday to Friday)

Serious Adverse Event Reporting
Fax:  +44 (0) 121 414 2230    or   +44 (0) 121 414 3700

Sponsor
University of Birmingham
Edgbaston
Birmingham
B15 2TT